Matthew D Hellmann

Matthew D Hellmann

UNVERIFIED PROFILE

Are you Matthew D Hellmann?   Register this Author

Register author
Matthew D Hellmann

Matthew D Hellmann

Publications by authors named "Matthew D Hellmann"

Are you Matthew D Hellmann?   Register this Author

97Publications

7903Reads

46Profile Views

Use of Circulating Tumor DNA for Cancer Immunotherapy.

Clin Cancer Res 2019 Dec 8;25(23):6909-6915. Epub 2019 Jul 8.

Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-18-2688DOI Listing
December 2019

Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer.

N Engl J Med 2019 11 28;381(21):2020-2031. Epub 2019 Sep 28.

From the Memorial Sloan Kettering Cancer Center, New York (M.D.H.); Hospital Universitario Doce de Octubre, Centro Nacional de Investigaciones Oncológicas, Universidad Complutense, and Centro de Investigación Biomédica en Red de Cáncer, Madrid (L.P.-A.), Hospital Universitario Virgen Del Rocio, Seville (R.B.C.), and the Catalan Institute of Oncology-Germans Trias i Pujol Hospital, Badalona (E.C.C.) - all in Spain; Ambulatorium Chemioterapii, Bydgoszcz, Poland (B.Z.); the Asan Medical Center (S.-W.K.) and the Samsung Medical Center at Sungkyunkwan University School of Medicine (K.P.) - both in Seoul, South Korea; the Institute of Oncology Prof. Dr. Alexandru Trestioreanu, Bucharest, Romania (A.A.); the Hospital Italiano de Buenos Aires, Buenos Aires (L.L.); Instituto Jalisciense de Cancerologia, Guadalajara, Mexico (E.M.J.); the Saitama Cancer Center, Saitama, Japan (H.S.); Matrai Gyogyintezet, Matrahaza, Hungary (I.A.); Limoges University Hospital, Limoges (A.V.), and Aix-Marseille University, National Center for Scientific Research, INSERM, Centre de Recherche en Cancérologie de Marseille, Assistance Publique-Hôpitaux de Marseille, Marseille (F.B.) - all in France; Centre Hospitalier Universitaire Vaudois, Lausanne University, Lausanne, Switzerland (S.P.); Sotiria General Hospital, National and Kapodistrian University of Athens, Athens (K.S.); Lung Clinic Grosshansdorf, Airway Research Center North, German Center of Lung Research, Grosshansdorf, Germany (M.R.); Fox Chase Cancer Center, Philadelphia (H.B.); Johns Hopkins Kimmel Cancer Center, Baltimore (J.R.B.); Princess Alexandra Hospital, Brisbane, QLD, Australia (K.J.O.); Bristol-Myers Squibb, Princeton, NJ (W.J.G., P.B., S.K.R., R.S.K., F.E.N.); and Winship Cancer Institute, Emory University, Atlanta (S.S.R.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1910231DOI Listing
November 2019

Utilization and factors precluding the initiation of consolidative durvalumab in unresectable stage III non-small cell lung cancer.

Radiother Oncol 2019 Nov 28;144:101-104. Epub 2019 Nov 28.

Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.radonc.2019.11.015DOI Listing
November 2019

Concurrent RB1 and TP53 Alterations Define a Subset of EGFR-Mutant Lung Cancers at risk for Histologic Transformation and Inferior Clinical Outcomes.

J Thorac Oncol 2019 Oct 19;14(10):1784-1793. Epub 2019 Jun 19.

Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York; Weill Cornell Medical College, New York, New York. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2019.06.002DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6764905PMC
October 2019

Opposing Functions of Interferon Coordinate Adaptive and Innate Immune Responses to Cancer Immune Checkpoint Blockade.

Cell 2019 Aug;178(4):933-948.e14

Department of Radiation Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA; Institute for Immunology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA; Parker Institute for Cancer Immunotherapy, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA; Abramson Family Cancer Research Institute, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cell.2019.07.019DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6830508PMC
August 2019

How to Make the Best Use of Immunotherapy as First-Line Treatment for Advanced/Metastatic Non-Small-Cell Lung Cancer.

Ann Oncol 2019 Mar 26. Epub 2019 Mar 26.

Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, and Parker Center for Cancer Immunotherapy, New York, NY, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/annonc/mdz109DOI Listing
March 2019

Tumor Mutation Burden and Efficacy of EGFR-Tyrosine Kinase Inhibitors in Patients with -Mutant Lung Cancers.

Clin Cancer Res 2019 02 25;25(3):1063-1069. Epub 2018 Jul 25.

Department of Medicine, Division of Solid Tumor Oncology, Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, New York, New York.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-18-1102DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6347551PMC
February 2019

Adding to the checkpoint blockade armamentarium.

Nat Med 2019 02;25(2):203-205

Merck, Rahway, NJ, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41591-019-0350-5DOI Listing
February 2019

Acquired resistance to immunotherapy in MMR-D pancreatic cancer.

J Immunother Cancer 2018 11 20;6(1):127. Epub 2018 Nov 20.

Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40425-018-0448-1DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6247688PMC
November 2018

Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non-Small-Cell Lung Cancer.

J Clin Oncol 2018 10 20;36(28):2872-2878. Epub 2018 Aug 20.

Matthew D. Hellmann, Parker Institute for Cancer Immunotherapy; Kathryn C. Arbour, Niamh Long, Hira Rizvi, Andy Ni, W. Victoria Lai, Joshua K. Sabari, Andrew J. Plodkowski, Darragh Halpenny, Jamie E. Chaft, Gregory J. Riely, and Matthew D. Hellmann, Memorial Sloan Kettering Cancer Center; Kathryn C. Arbour, W. Victoria Lai, Joshua K. Sabari, Jamie E. Chaft, Gregory J. Riely, and Matthew D. Hellmann, Weill Cornell Medical College, New York, NY; Laura Mezquita, Roberto Ferrara, Lizza E.L. Hendriks, Caroline Caramella, Benjamin Besse, and David Planchard, Gustave Roussy Cancer Center, Villejuif; Edouard Auclin, Hôpital Européen Georges Pompidou; Benjamin Besse, Paris-Sud University, Le Kremlin Bicêtre, Paris, France; Gala Martínez-Bernal, Virgen del Rocío Hospital, Seville, Spain; Lizza E.L. Hendriks, Maastricht University Medical Center, Maastricht, the Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2018.79.0006DOI Listing
October 2018

Safety and Efficacy of Re-treating with Immunotherapy after Immune-Related Adverse Events in Patients with NSCLC.

Cancer Immunol Res 2018 09 10;6(9):1093-1099. Epub 2018 Jul 10.

Department of Medicine, Thoracic Oncology Service, Division of Solid Tumor Oncology, Memorial Sloan Kettering Cancer Center, New York, New York.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2326-6066.CIR-17-0755DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6125223PMC
September 2018

Lung Cancer with a High Tumor Mutational Burden.

N Engl J Med 2018 09;379(11):1093-1094

Hospital Universitario 12 de Octubre, Madrid, Spain

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMc1808566DOI Listing
September 2018

Safety of Programmed Death-1 Pathway Inhibitors Among Patients With Non-Small-Cell Lung Cancer and Preexisting Autoimmune Disorders.

J Clin Oncol 2018 07 10;36(19):1905-1912. Epub 2018 May 10.

Giulia C. Leonardi, Sasha Kravets, Suzanne E. Dahlberg, and Mark M. Awad, Dana-Farber Cancer Institute; Justin F. Gainor and Roxana Azimi, Massachusetts General Hospital; Lydia Gedmintas, Brigham and Women's Hospital, Boston, MA; Mehmet Altan, MD Anderson Cancer Center, Houston, TX; Hira Rizvi and Matthew D. Hellmann, Memorial Sloan Kettering Cancer Center; Matthew D. Hellmann, Weill Cornell Medical College, and Parker Institute for Cancer Immunotherapy, New York, NY; and Jonathan W. Riess, University of California Davis Comprehensive Cancer Center, Sacramento, CA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.77.0305DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6553840PMC
July 2018

Mutations and PD-1 Inhibitor Resistance in -Mutant Lung Adenocarcinoma.

Cancer Discov 2018 07 17;8(7):822-835. Epub 2018 May 17.

Department of Thoracic and Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2159-8290.CD-18-0099DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6030433PMC
July 2018

Non-conventional Inhibitory CD4Foxp3PD-1 T Cells as a Biomarker of Immune Checkpoint Blockade Activity.

Cancer Cell 2018 06;33(6):1017-1032.e7

Ludwig Collaborative and Swim Across America Laboratory, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Parker Institute for Cancer Immunotherapy, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Weill Cornell Medicine, New York, NY 10065, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ccell.2018.05.009DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6648657PMC
June 2018

Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer.

Cancer Cell 2018 05 12;33(5):843-852.e4. Epub 2018 Apr 12.

Department of Medicine, Memorial Sloan Kettering Cancer Center, 885 2(nd) Avenue, New York, NY 10017, USA; Weill Cornell School of Medicine, New York, NY, USA; Parker Institute for Cancer Immunotherapy, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Ludwig Collaborative Laboratory, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15356108183012
Publisher Site
http://dx.doi.org/10.1016/j.ccell.2018.03.018DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5953836PMC
May 2018

Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden.

N Engl J Med 2018 May 16;378(22):2093-2104. Epub 2018 Apr 16.

From Memorial Sloan Kettering Cancer Center Hospital, New York (M.D.H.); Prof. Dr. Ion Chiricuta Institute of Oncology and Universitatea de Medicina si Farmacie Iuliu Hatieganu, Cluj-Napoca, Romania (T.-E.C.); Centrum Onkologii-Instytut im. Marii Sklodowskiej-Curie, Warsaw, Poland (A.P.); Seoul National University Bundang Hospital, Seoul, South Korea (J.S.L.); Ohio State University, Columbus (G.A.O.); Hôpital Sainte Musse, Toulon, France (C.A.-V.); Ospedale Santa Maria della Misericordia, Perugia, Italy (E.M.); First Department of Oncology, Metropolitan Hospital, Athens, Greece (H.L.); Antoni van Leeuwenhoek Ziekenhuis, Amsterdam (S.B.); Fundación Arturo López Pérez, Santiago, Chile (P.S.); Fox Chase Cancer Center, Philadelphia (H.B.); Winship Cancer Institute, Emory University, Atlanta (S.S.R.); Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore (J.B.); LungenClinic Grosshansdorf, Airway Research Center North, German Center for Lung Research, Grosshansdorf, Germany (M.R.); Princess Alexandra Hospital, Brisbane, QLD, Australia (K.J.O.); Bristol-Myers Squibb, Princeton, NJ (W.J.G., G.G., H.C., J.S., P.B., D.H., Y.F., F.N.); and Hospital Universitario 12 de Octubre, Centro Nacional de Investigaciones Oncológicas, Universidad Complutense, and CiberOnc, Madrid (L.P.-A.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1801946DOI Listing
May 2018

Neoadjuvant PD-1 Blockade in Resectable Lung Cancer.

N Engl J Med 2018 May 16;378(21):1976-1986. Epub 2018 Apr 16.

From the Bloomberg-Kimmel Institute for Cancer Immunotherapy and the Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore (P.M.F., K.N.S., V.A., T.R.C., M.Z., S.C.Y., S.B., R.J.B., J.N., K.A.M., F.V., H.G., J.Z., J.X.C., H.Y.C., J.-W.S., R.B.S., J.W., E.G., H.W., G.L.R., J.M.T., V.E.V., S.L.T., J.R.B., D.M.P.); Memorial Sloan Kettering Cancer Center and Weill Cornell Medicine (J.E.C., M.D.H., D.R.J., M.J.V., N.R., Z.O., V.R., J.D.W., T.M.) and the Ludwig Collaborative (J.D.W., T.M.) - all in New York; the Parker Institute for Cancer Immunotherapy, San Francisco (J.D.W., T.M.); and Swim Across America Laboratory, Charlotte, NC (J.D.W., T.M.).

View Article

Download full-text PDF

Source
http://www.nejm.org/doi/10.1056/NEJMoa1716078
Publisher Site
http://dx.doi.org/10.1056/NEJMoa1716078DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6223617PMC
May 2018

Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non-Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing.

J Clin Oncol 2018 03 16;36(7):633-641. Epub 2018 Jan 16.

Hira Rizvi, Francisco Sanchez-Vega, Konnor La, Walid Chatila, Philip Jonsson, Darragh Halpenny, Andrew Plodkowski, Niamh Long, Jennifer L. Sauter, Natasha Rekhtman, Travis Hollmann, Ronglai Shen, Ai Ni, Kathryn C. Arbour, Taha Merghoub, Jedd Wolchok, Jamie E. Chaft, Mark G. Kris, Charles M. Rudin, Nicholas D. Socci, Michael F. Berger, Barry S. Taylor, Ahmet Zehir, David B. Solit, Maria E. Arcila, Marc Ladanyi, Gregory J. Riely, Nikolaus Schultz, and Matthew D. Hellmann, Memorial Sloan Kettering Cancer Center; Taha Merghoub, Jedd Wolchok, Alexandra Snyder, Jamie E. Chaft, Mark G. Kris, Charles M. Rudin, Gregory J. Riely, and Matthew D. Hellmann, Weill Cornell Medical College, New York, NY; Kurt A. Schalper, Yale School of Medicine, New Haven, CT; Justin F. Gainor, Massachusetts General Hospital, Boston, MA; and Alexandra Snyder, Adaptive Biotechnologies, Seattle, WA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.75.3384DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6075848PMC
March 2018

Adverse Events Associated with Immune Checkpoint Blockade.

N Engl J Med 2018 03;378(12):1165

Memorial Sloan Kettering Cancer Center, New York, NY

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMc1801663DOI Listing
March 2018

Immune-Related Adverse Events Associated with Immune Checkpoint Blockade.

N Engl J Med 2018 01;378(2):158-168

From Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMra1703481DOI Listing
January 2018

Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057).

J Clin Oncol 2017 Dec 12;35(35):3924-3933. Epub 2017 Oct 12.

Leora Horn, Vanderbilt-Ingram Cancer Center; David R. Spigel, Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN; Everett E. Vokes, University of Chicago, Chicago, IL; Esther Holgado, Hospital De Madrid, Norte Sanchinarro, Madrid; Enriqueta Felip, Hospital Universitari Vall d'Hebron, Barcelona; Luis Paz-Ares, Hospital Universitario Virgen Del Rocio, Seville, Spain; Neal Ready, Duke University Medical Center, Durham, NC; Martin Steins, Thoraxklinik-Heidelberg gGmbH, Heidelberg; Martin Kohlhäeufl, Robert-Bosch-Krankenhaus, Stuttgart; Martin Reck, LungenClinic Grosshansdorf, Airway Research Center North, German Center for Lung Research, Grosshansdorf; Wilfried E.E. Eberhardt, University Hospital and Ruhrlandclinic, University of Duisburg-Essen, Essen, Germany; Elena Poddubskaya, N.N. Blokhin Russian Cancer Research Center, Moscow, Russia; Hossein Borghaei, Fox Chase Cancer Center, Philadelphia, PA; Adam Pluzanski, Centrum Onkologii-Instytut Im. Marii Sklodowskiej-Curie, Warsaw, Poland; Karen L. Reckamp, City of Hope, Duarte, CA; Marco A. Burgio and Lucio Crinò, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Istituto Scientifico Romagnolo Per lo Studio e la Cura dei Tumori, Meldola, Italy; David Waterhouse, Oncology Hematology Care (OHC)/US Oncology, Cincinnati, OH; Fabrice Barlesi, Aix-Marseille Université, Assistance Publique Hôpitaux de Marseille, Marseille; Jérôme Fayette, Léon Bérard, Lyon, France; Scott Antonia, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL; Oscar Arrieta, Instituto Nacional De Cancerologia, Mexico City, Mexico; Naiyer Rizvi and Matthew D. Hellmann, Memorial Sloan Kettering Cancer Center, New York, NY; William J. Geese, Ang Li, Anne Blackwood-Chirchir, and Diane Healey, Bristol-Myers Squibb, Princeton, NJ; and Julie Brahmer, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.74.3062DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6075826PMC
December 2017

Cutaneous Eruptions in Patients Receiving Immune Checkpoint Blockade: Clinicopathologic Analysis of the Nonlichenoid Histologic Pattern.

Am J Surg Pathol 2017 Oct;41(10):1381-1389

Departments of *Dermatology ‡Pathology §Oncology, Johns Hopkins University School of Medicine and Sidney Kimmel Comprehensive Cancer Center ∥The Brady Urologic Institute, Johns Hopkins University School of Medicine, Baltimore, MD Departments of †Medicine, Thoracic Oncology Service ¶Pathology #Dermatology, Memorial Sloan Kettering Cancer Center, New York, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/PAS.0000000000000900DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5657299PMC
October 2017

Initial Experience With Lung Cancer Resection After Treatment With T-Cell Checkpoint Inhibitors.

Ann Thorac Surg 2017 Sep;104(3):e217-e218

Thoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.athoracsur.2017.03.038DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5572805PMC
September 2017

Expression of PD-L1 and other immunotherapeutic targets in thymic epithelial tumors.

PLoS One 2017 3;12(8):e0182665. Epub 2017 Aug 3.

Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, United States of America.

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0182665PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5542609PMC
August 2017

Erratum: Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients.

Authors:
Ahmet Zehir Ryma Benayed Ronak H Shah Aijazuddin Syed Sumit Middha Hyunjae R Kim Preethi Srinivasan Jianjiong Gao Debyani Chakravarty Sean M Devlin Matthew D Hellmann David A Barron Alison M Schram Meera Hameed Snjezana Dogan Dara S Ross Jaclyn F Hechtman Deborah F DeLair JinJuan Yao Diana L Mandelker Donavan T Cheng Raghu Chandramohan Abhinita S Mohanty Ryan N Ptashkin Gowtham Jayakumaran Meera Prasad Mustafa H Syed Anoop Balakrishnan Rema Zhen Y Liu Khedoudja Nafa Laetitia Borsu Justyna Sadowska Jacklyn Casanova Ruben Bacares Iwona J Kiecka Anna Razumova Julie B Son Lisa Stewart Tessara Baldi Kerry A Mullaney Hikmat Al-Ahmadie Efsevia Vakiani Adam A Abeshouse Alexander V Penson Philip Jonsson Niedzica Camacho Matthew T Chang Helen H Won Benjamin E Gross Ritika Kundra Zachary J Heins Hsiao-Wei Chen Sarah Phillips Hongxin Zhang Jiaojiao Wang Angelica Ochoa Jonathan Wills Michael Eubank Stacy B Thomas Stuart M Gardos Dalicia N Reales Jesse Galle Robert Durany Roy Cambria Wassim Abida Andrea Cercek Darren R Feldman Mrinal M Gounder A Ari Hakimi James J Harding Gopa Iyer Yelena Y Janjigian Emmet J Jordan Ciara M Kelly Maeve A Lowery Luc G T Morris Antonio M Omuro Nitya Raj Pedram Razavi Alexander N Shoushtari Neerav Shukla Tara E Soumerai Anna M Varghese Rona Yaeger Jonathan Coleman Bernard Bochner Gregory J Riely Leonard B Saltz Howard I Scher Paul J Sabbatini Mark E Robson David S Klimstra Barry S Taylor Jose Baselga Nikolaus Schultz David M Hyman Maria E Arcila David B Solit Marc Ladanyi Michael F Berger

Nat Med 2017 08;23(8):1004

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nm0817-1004cDOI Listing
August 2017

Making It Personal: Neoantigen Vaccines in Metastatic Melanoma.

Immunity 2017 08;47(2):221-223

Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Ave., New York, NY 10028, USA; Adaptive Biotechnologies, 1551 Eastlake Ave. E, Ste 200, Seattle, WA 98102, USA. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S10747613173033
Publisher Site
http://dx.doi.org/10.1016/j.immuni.2017.08.001DOI Listing
August 2017

Targeting the differential addiction to anti-apoptotic BCL-2 family for cancer therapy.

Nat Commun 2017 07 17;8:16078. Epub 2017 Jul 17.

Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, New York 10065, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/ncomms16078DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5520052PMC
July 2017

OncoKB: A Precision Oncology Knowledge Base.

JCO Precis Oncol 2017 Jul 16;2017. Epub 2017 May 16.

, Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA; , Gastrointestinal Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; , Gynecologic Medical Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; , Breast Medicine Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Weill Cornell Medical College, New York, NY USA; , Breast Medicine Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; , Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center , New York, NY, USA, Weill Cornell Medical College, New York, NY USA; , Head and Neck Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; , , Department of Hematology and Oncology, Quest Diagnostics Nichols Institute, 33608 Ortega Highway, San Juan Capistrano, CA, 92675, USA; , Department of R&D and Bioinformatics, Quest Diagnostics Nichols Institute, 33608 Ortega Highway, San Juan Capistrano, CA, 92675, USA; , Head and Neck Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Weill Cornell Medical College, New York, NY USA; , Melanoma and Immunotherapeutics Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Weill Cornell Medical College, New York, NY USA; , Gynecologic Medical Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; , Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Sarcoma Medical Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, USA, Weill Cornell Medical College, New York, NY USA; Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Weill Cornell Medical College, New York, NY USA; , Developmental Therapeutics, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Sarcoma Medical Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, USA, Weill Cornell Medical College, New York, NY USA; , Gastrointestinal Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Weill Cornell Medical College, New York, NY USA; , Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY, USA; , Brain Tumor Center, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY, USA; , Department of Oncology and Internal Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Weill Cornell Medical College, New York, NY USA; , Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY, USA; , Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA , Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA; , Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA; , Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA; , Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA; , Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Developmental Therapeutics, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; , Breast Medicine Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Developmental Therapeutics, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Weill Cornell Medical College, New York, NY USA; , Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Weill Cornell Medical College, New York, NY USA; , Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

View Article

Download full-text PDF

Source
https://www.researchgate.net/profile/Debyani_Chakravarty/pub
Web Search
http://ascopubs.org/doi/10.1200/PO.17.00011
Publisher Site
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5586540PMC
http://dx.doi.org/10.1200/PO.17.00011DOI Listing
July 2017

Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients.

Authors:
Ahmet Zehir Ryma Benayed Ronak H Shah Aijazuddin Syed Sumit Middha Hyunjae R Kim Preethi Srinivasan Jianjiong Gao Debyani Chakravarty Sean M Devlin Matthew D Hellmann David A Barron Alison M Schram Meera Hameed Snjezana Dogan Dara S Ross Jaclyn F Hechtman Deborah F DeLair JinJuan Yao Diana L Mandelker Donavan T Cheng Raghu Chandramohan Abhinita S Mohanty Ryan N Ptashkin Gowtham Jayakumaran Meera Prasad Mustafa H Syed Anoop Balakrishnan Rema Zhen Y Liu Khedoudja Nafa Laetitia Borsu Justyna Sadowska Jacklyn Casanova Ruben Bacares Iwona J Kiecka Anna Razumova Julie B Son Lisa Stewart Tessara Baldi Kerry A Mullaney Hikmat Al-Ahmadie Efsevia Vakiani Adam A Abeshouse Alexander V Penson Philip Jonsson Niedzica Camacho Matthew T Chang Helen H Won Benjamin E Gross Ritika Kundra Zachary J Heins Hsiao-Wei Chen Sarah Phillips Hongxin Zhang Jiaojiao Wang Angelica Ochoa Jonathan Wills Michael Eubank Stacy B Thomas Stuart M Gardos Dalicia N Reales Jesse Galle Robert Durany Roy Cambria Wassim Abida Andrea Cercek Darren R Feldman Mrinal M Gounder A Ari Hakimi James J Harding Gopa Iyer Yelena Y Janjigian Emmet J Jordan Ciara M Kelly Maeve A Lowery Luc G T Morris Antonio M Omuro Nitya Raj Pedram Razavi Alexander N Shoushtari Neerav Shukla Tara E Soumerai Anna M Varghese Rona Yaeger Jonathan Coleman Bernard Bochner Gregory J Riely Leonard B Saltz Howard I Scher Paul J Sabbatini Mark E Robson David S Klimstra Barry S Taylor Jose Baselga Nikolaus Schultz David M Hyman Maria E Arcila David B Solit Marc Ladanyi Michael F Berger

Nat Med 2017 Jun 8;23(6):703-713. Epub 2017 May 8.

Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York, USA.

View Article

Download full-text PDF

Source
http://www.nature.com/doifinder/10.1038/nm.4333
Publisher Site
http://dx.doi.org/10.1038/nm.4333DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5461196PMC
June 2017

Prognostic impact of TTF-1 expression in patients with stage IV lung adenocarcinomas.

Lung Cancer 2017 06 28;108:205-211. Epub 2017 Mar 28.

Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, 300 E 66(th) St., New York, NY 10065, USA; Department of Medicine, Weill Cornell Medical College, 1300 York Ave., New York, NY 10065, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2017.03.015DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6423973PMC
June 2017

Reply to M. Nishino et al.

J Clin Oncol 2017 05 6;35(14):1629-1630. Epub 2017 Feb 6.

Jarushka Naidoo, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD; Tunc Iyriboz and Jane Cunningham, Memorial Sloan Kettering Cancer Center, New York, NY; and Matthew D. Hellmann, Memorial Sloan Kettering Cancer Center; and Weill Cornell Medical College, New York, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.71.6639DOI Listing
May 2017

Thinking Critically About Classifying Adverse Events: Incidence of Pancreatitis in Patients Treated With Nivolumab + Ipilimumab.

J Natl Cancer Inst 2017 04 31;109(4). Epub 2016 Dec 31.

Affiliations of authors: Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY (CFF, VC, TB, ANS, PM, MKC, JDW, PBC, MDH, MAP); Weill Cornell Medical College, New York, NY (CFF, AVR, ANS, PM, MKC, JDW, PBC, MDH, MAP).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/djw260DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5441295PMC
April 2017

Pneumonitis in Patients Treated With Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy.

J Clin Oncol 2017 Mar 30;35(7):709-717. Epub 2016 Sep 30.

Jarushka Naidoo, Kaitlin M. Woo, Tunc Iyriboz, Darragh Halpenny, Jane Cunningham, Jamie E. Chaft, Neil H. Segal, Margaret K. Callahan, Alexander M. Lesokhin, Jonathan Rosenberg, Martin H. Voss, Charles M. Rudin, Hira Rizvi, Xue Hou, Katherine Rodriguez, Melanie Albano, Ruth-Ann Gordon, Charles Leduc, Natasha Rekhtman, Bianca Harris, Jedd D. Wolchok, Michael A. Postow, and Matthew D. Hellmann, Memorial Sloan Kettering Cancer Center; Jamie E. Chaft, Neil H. Segal, Margaret K. Callahan, Alexander M. Lesokhin, Jonathan Rosenberg, Martin H. Voss, Charles M. Rudin, Jedd D. Wolchok, Michael A. Postow, and Matthew D. Hellmann, Weill Cornell Medical College, New York, NY; Jarushka Naidoo, Sidney Kimmel Cancer Center at Johns Hopkins University, Baltimore, MD; Xuan Wang, Peking University Cancer Hospital and Institute, Beijing; Xue Hou, Sun Yat-sen University Cancer Center, Guangdong Province, People's Republic of China; Xuan Wang, Matteo S. Carlino, Benjamin Y. Kong, and Georgina V. Long, The University of Sydney; Alexander M. Menzies and Alexander D. Guminski, Royal North Shore and Mater Hospital; and Matteo S. Carlino and Benjamin Y. Kong, Westmead and Blacktown Hospitals, Sydney, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.68.2005DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5559901PMC
March 2017

Combinatorial Cancer Immunotherapies.

Adv Immunol 2016 12;130:251-77. Epub 2016 Jan 12.

Memorial Sloan Kettering Cancer Center, New York, NY, United States; Weill Cornell Medical College, New York, NY, United States. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/bs.ai.2015.12.005DOI Listing
October 2016

Nivolumab in Combination With Platinum-Based Doublet Chemotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer.

J Clin Oncol 2016 09 27;34(25):2969-79. Epub 2016 Jun 27.

Naiyer A. Rizvi and Matthew D. Hellmann, Memorial Sloan Kettering Cancer Center, New York, NY; Julie R. Brahmer, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Rosalyn A. Juergens, Juravinski Cancer Centre at McMaster University, Hamilton; Scott A. Laurie, Ottawa Hospital Cancer Centre, Ottawa; Frances A. Shepherd, Princess Margaret Cancer Centre, Toronto, Ontario, Canada; Hossein Borghaei, Fox Chase Cancer Center, Philadelphia, PA; Scott Gettinger, Yale Cancer Center, New Haven, CT; Laura Q. Chow, University of Washington, Seattle, WA; David E. Gerber, University of Texas Southwestern Medical Center, Dallas, TX; Jonathan W. Goldman, University of California, Los Angeles, Los Angeles, CA; Allen C. Chen, Yun Shen, Faith E. Nathan, and Christopher T. Harbison, Bristol-Myers Squibb, Princeton, NJ; and Scott Antonia, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2016.66.9861
Publisher Site
http://dx.doi.org/10.1200/JCO.2016.66.9861DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5569693PMC
September 2016

Nivolumab Monotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer.

J Clin Oncol 2016 09 27;34(25):2980-7. Epub 2016 Jun 27.

Scott Gettinger, Yale Cancer Center, New Haven, CT; Naiyer A. Rizvi and Matthew D. Hellmann, Memorial Sloan Kettering Cancer Center, New York, NY; Laura Q. Chow, University of Washington, Seattle, WA; Hossein Borghaei, Fox Chase Cancer Center, Philadelphia, PA; Julie Brahmer, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Neal Ready, Duke University Medical Center, Durham, NC; David E. Gerber, University of Texas Southwestern Medical Center, Dallas, TX; Frances A. Shepherd, Princess Margaret Cancer Centre, Toronto; Rosalyn A. Juergens, Juravinski Cancer Centre at McMaster University, Hamilton; Scott A. Laurie, Ottawa Hospital Cancer Centre, Ottawa, Ontario, Canada; Scott Antonia, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL; Jonathan W. Goldman, University of California, Los Angeles, Los Angeles, CA; and Faith E. Nathan, Yun Shen, and Christopher T. Harbison, Bristol-Myers Squibb, Princeton, NJ.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.66.9929DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5569692PMC
September 2016

Phase II Study of a Non-Platinum-Containing Doublet of Paclitaxel and Pemetrexed with Bevacizumab as Initial Therapy for Patients with Advanced Lung Adenocarcinomas.

J Thorac Oncol 2016 06 8;11(6):890-9. Epub 2016 Mar 8.

Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York; Department of Medicine, Weill Cornell Medical College, New York, New York. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2016.02.018DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4877255PMC
June 2016

Medians and Milestones in Describing the Path to Cancer Cures: Telling "Tails".

JAMA Oncol 2016 Feb;2(2):167-8

Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, New York, New York2Weill Cornell Medical College, New York, New York.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamaoncol.2015.4345DOI Listing
February 2016

Chemotherapy for lung cancers: here to stay.

Am Soc Clin Oncol Educ Book 2014 :e375-80

From the Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.14694/EdBook_AM.2014.34.e375DOI Listing
December 2015

Impact of Concurrent PIK3CA Mutations on Response to EGFR Tyrosine Kinase Inhibition in EGFR-Mutant Lung Cancers and on Prognosis in Oncogene-Driven Lung Adenocarcinomas.

J Thorac Oncol 2015 Dec;10(12):1713-9

*Thoracic Oncology Service, Department of Medicine, †Department of Epidemiology and Biostatistics, ‡Department of Radiology, and §Department of Pathology, Memorial Sloan Kettering Cancer Center (MSKCC), New York, NY.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15560864153509
Publisher Site
http://dx.doi.org/10.1097/JTO.0000000000000671DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4760768PMC
December 2015

Preliminary Safety, Pharmacokinetics, and Efficacy of Regorafenib, Cisplatin, and Pemetrexed in Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancers.

Clin Lung Cancer 2015 Nov 20;16(6):514-22. Epub 2015 Apr 20.

Department of Medicine, Section of Medical Oncology, Yale University School of Medicine, Yale Cancer Center, New Haven, CT.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cllc.2015.04.003DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4750397PMC
November 2015

Differences in the survival of patients with recurrent versus de novo metastatic KRAS-mutant and EGFR-mutant lung adenocarcinomas.

Cancer 2015 Jun 17;121(12):2078-82. Epub 2015 Mar 17.

Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.29313DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4783794PMC
June 2015

Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer.

J Clin Oncol 2015 Jun 20;33(18):2004-12. Epub 2015 Apr 20.

Scott N. Gettinger and Mario Sznol, Yale Cancer Center, New Haven, CT; Leora Horn, David P. Carbone, and Jeffrey A. Sosman, Vanderbilt University Medical Center; David R. Spigel, Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN; Leena Gandhi, David M. Jackman, and F. Stephen Hodi, Dana-Farber Cancer Institute; Rebecca S. Heist and Lecia V. Sequist, Massachusetts General Hospital Cancer Center; David F. McDermott, Beth Israel Deaconess Medical Center, Boston, MA; Scott J. Antonia and Mary C. Pinder-Schenck, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL; Naiyer A. Rizvi, Richard D. Carvajal, and Matthew D. Hellmann, Memorial Sloan Kettering Cancer Center, New York, NY; John D. Powderly, Carolina BioOncology Institute, Huntersville, NC; David C. Smith, University of Michigan, Ann Arbor, MI; Philip Leming, Christ Hospital Cancer Center, Cincinnati, OH; Suzanne L. Topalian, Drew M. Pardoll, and Julie R. Brahmer, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins, Baltimore, MD; and Vindira Sankar, Christoph M. Ahlers, Mark Salvati, Jon M. Wigginton, Georgia D. Kollia, and Ashok K. Gupta, Bristol-Myers Squibb, Princeton, NJ.

View Article

Download full-text PDF

Source
http://jco.ascopubs.org/content/early/2015/04/15/JCO.2014.58
Web Search
http://jco.ascopubs.org/cgi/doi/10.1200/JCO.2014.58.3708
Publisher Site
http://dx.doi.org/10.1200/JCO.2014.58.3708DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4672027PMC
June 2015

Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer.

Science 2015 Apr 12;348(6230):124-8. Epub 2015 Mar 12.

Weill Cornell Medical College, New York, NY, 10065, USA. Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA. Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1126/science.aaa1348DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4993154PMC
April 2015

Clinical characteristics and course of 63 patients with BRAF mutant lung cancers.

J Thorac Oncol 2014 Nov;9(11):1669-74

Departments of *Medicine, Thoracic Oncology Service, Division of Solid Tumor Oncology, †Epidemiology and Biostatistics, and ‡Pathology, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JTO.0000000000000344DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4251710PMC
November 2014

Clinical and in vivo evidence that EGFR S768I mutant lung adenocarcinomas are sensitive to erlotinib.

J Thorac Oncol 2014 Oct;9(10):e73-4

*Thoracic Oncology Service, Department of Medicine; †Computational Biology Center; ‡Thoracic Service, Department of Surgery; §Department of Pathology, Memorial Sloan-Kettering Cancer Center; and ‖Weill Cornell Medical College, New York, NY.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15560864153071
Publisher Site
http://dx.doi.org/10.1097/JTO.0000000000000221DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4655969PMC
October 2014

Opportunistic infections in patients treated with immunotherapy for cancer.

J Immunother Cancer 2014 18;2:19. Epub 2014 Jun 18.

Memorial Sloan-Kettering Cancer Center, Melanoma and Immunotherapeutics Oncology Service, 300 East 66th Street, New York, NY 10065, USA.

View Article

Download full-text PDF

Source
http://jitc.biomedcentral.com/articles/10.1186/2051-1426-2-1
Publisher Site
http://dx.doi.org/10.1186/2051-1426-2-19DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4079190PMC
July 2014

Risk of hemoptysis in patients with resected squamous cell and other high-risk lung cancers treated with adjuvant bevacizumab.

Cancer Chemother Pharmacol 2013 Aug 28;72(2):453-61. Epub 2013 Jun 28.

Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan-Kettering Cancer Center, Weill Cornell Medical School, 300 East 66th Street, New York, NY 10065, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-013-2219-5DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4653739PMC
August 2013